Overview

KRN5500 in Treating Patients With Solid Tumors

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Phase I trial to study the effectiveness of KRN5500 in treating patients who have solid tumors. Drugs used in chemotherapy, such as KRN5500, work in different ways to stop cancer cells from dividing so they stop growing or die

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

KRN 5500